SYMPOSIA

Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Poster Presentations
[PP-082] Ref. No: 159
Foetality in schizophrenia
Elif Mutlu, Mehmet Emin Ceylan, Agah Aydın
Bakırköy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, İstanbul, Turkey
E-mail: elifmutlu@yahoo.com
Objective: The aim of this study was to evaluate common morphological and neurological features of schizophrenia from an ontogenetic
perspective and to propose a new conceptual approach to schizophrenia, in which early foetal marks persist without diminishing in
comparison to other people.
Material and Methods: Fifty patients diagnosed with schizophrenia from the Bakırköy Research and Training Hospital for Psychiatry,
Neurology and Neurosurgery were chosen for the study group. The control group consists of fifty healthy male subjects. The ages of
all subjects varied between 18 and 65. All of the subjects were informed about the study and their written consents were obtained.
Sociodemographic data of all subjects were recorded and the Waldrop Minor Physical Anomalies Scale, the NES ( neurological evaluation
scale), and the Edinburgh Handedness Inventory were applied.
Results: We found significantly higher scores among schizophrenic patients in comparison to healthy subjects both in the NES total and
all four sub-categories of the scale. The minor physical anomalies scores, head circumference, and hypertelorism were significantly higher
in the schizophrenic group. In addition, for hand-eye dominancy, we observed more tendency to be crosswise.
Conclusion: Some characteristics of schizophrenia such as hypertelorism, large head circumference, high palate, thin muscle and
bone structure, primitive reflexes, mental and behavioral characteristics could be evaluated as a separate ontogenetic entity.Evaluating
schizophrenia within the context of a neurodevelopmental hypothesis, as an evolutionary process, in which foetal traits persist, would
contribute to our understanding of the disorder’s ambigous nature and phenomenology.
Key words: Schizophrenia, foetality, ontogenesis
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S171
[PP-083] Ref. No: 182
Metabolic changes in the acute phase with olanzapine treatment
Mehmet Ak 1 , Abdullah Bolu 1 , Süleyman Akarsu 1 , Deniz Sezlev 2 , Tülin Yanık 2 , Özcan Uzun 1 , Fuat Özgen 1 , Aytekin Özşahin 1
1Department of Psychiatry, Gulhane Military Medical Faculty, Ankara, Turkey
2METU, Faculty of Science, Biology department, Ankara, Turkey
E-mail: drmehmetak@gmail.com
Introduction: Atypical antipsychotics are used in treatment of psychotic disorders and severe behavior disorders. Despite the lack of extra
pyramidal side effects, they cause metabolic disorders (such as hyperlipidemia, weight gain, glucose intolerance), which are important
causes of mortality (1). The exact mechanisms of these side-effects of atypical antipsychotics have not been identified so far and therefore
and protective measures could not be established (2). In this study we aimed to examine the acute phase changes in blood lipid profile
and body mass index while using olanzapine.
Materials and Methods: Twenty four patients, who were diagnosed with first-episode psychotic disorder and received olanzapine
treatment in the Department of Psychiatry, Gulhane Military Medical Faculty, were enrolled in the study. The serum lipid levels and fasting
blood sugars were measured before the treatment and four weeks after the treatment; body mass index was calculated and the data
obtained were compared.
Results: The comparison of pre- and post-treatment data showed significant increases in the weight gain, measurement of waist
circumference, body mass index, total cholesterol, and VLDL levels (p